Illumina remains focused on achieving a positive resolution regarding its inclusion on the UEL and is committed to serving customers in this important market. For two decades, Illumina has been proud ...

Illumina Inc. said the Chinese government has lifted a ban on the company selling its DNA sequencing machines inside the ...

Hepta, a biotechnology company using transformer-based AI to read the cell-free DNA (cfDNA) epigenome and detect organ-specific signals of chronic disease, today emerged from stealth with $6.7 million ...

At the booth of Gilead Sciences, Lenacapavir, to be used as the world's only twice-yearly, long-acting injectable for HIV ...

Key opportunities in the precision oncology market include the rising adoption of personalized therapies, growth in ...

Genomics company Illumina (NASDAQ:ILMN) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales were ...

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...

The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...

The manuscript concerns a fundamental and controversial question in Trypanosoma brucei biology and the parasite life cycle, providing further evidence that slender bloodstream forms can indeed infect ...

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related ...

Illumina’s revenue was flat for the third quarter as the sequencing giant continues to deal with headwinds from a China sales ...

Discover key Q3 2025 earnings insights for Illumina, including raised outlook, NovaSeq X growth, and margin expansion.